Cutler Group’s Rigel Pharmaceuticals RIGL Stock Holding History

Cutler Group’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-750	Closed	-$3K	–	4701
2019 Q1	$3K	Buy	+750	New	+$17.1K	﹤0.01%	3241

Other funds holding RIGL

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Cutler Group's RIGL Position: Q1 2024 in Review

Cutler Group sold out of Rigel Pharmaceuticals (RIGL) in Q1 2024, closing a stake of 120 shares — an estimated $1K sold.

Cutler Group first reported a position in RIGL in Q1 2016 and held it in 22 quarters. The position peaked at $31K in Q4 2020. 117 funds tracked by Wall St. Rank hold RIGL as of Q1 2024.

Cutler Group reported no remaining Rigel Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Cutler Group sold 120 Rigel Pharmaceuticals shares in Q1 2024, an estimated $1K.
Cutler Group first reported a position in Rigel Pharmaceuticals in Q1 2016 and held it in 22 quarters.
Cutler Group's Rigel Pharmaceuticals position peaked at $31K in Q4 2020.
117 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.